@BhallaResearch
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
Molecular Mechanisms of Kidney Disease, @StanfordNeph; Director, @Stanford_HTN; Director, @PreRenal_SU; @KidneyInCVD; @BhallaResearch@med-mastodon.com
Stanford, CA
Joined February 2020
- Tweets3.1K
- Following602
- Followers1.7K
- Likes27.2K
Thank you to @rmh199 @StanfordDeptMed for highlighting our work
Join nephrologist Dr. Vivek Bhalla (@BhallaResearch)
& Science Communicator Rebecca Handler (@rmh199) in the lab as he shares a story that began with a single patient’s case of early-onset kidney disease and led to a genetic discovery: youtube.com/watch?v=q0hiPi3_…
#Nephrology
Listening to past @ASNKidney president @proychaudhuryMD talking about the totality of new therapies of CKD and how to implement them…great time to be in Nephrology
Laboratory of Vivek Bhalla, MD- Stanford retweeted
D-24 until #Hypertension26 Oct 7-11 in Arlington, VA! We expect phenomenal sessions including cuffless 24hr ABPM in HTN management, SGLT2 inhibition in salt-sensitive HTN🫘↔️🫀, renal denervation for resistant HTN, GLP-1a in lowering BP, and many more! professional.heart.org/en/me…
Laboratory of Vivek Bhalla, MD- Stanford retweeted
I’m a doctor. This executive order is wrong. The President does not have the expertise to make these changes.
Vaccines are overwhelmingly safe. Vaccines are effective. Vaccines DO NOT cause autism.
Breaking up vaccines will mean children have to get more shots to get the same protection, not fewer shots. It will increase hesitancy and make children less safe.
Parents should listen to their child’s pediatrician about vaccines rather than listening to an inaccurate executive order. This is so wrong.
nitter.cf/axios/status/208688294…
Trump executive order would split up MMR vaccine axios.com/2026/08/10/trump-o…
Laboratory of Vivek Bhalla, MD- Stanford retweeted
Final call: Can you teach the kidney–heart connection better than a slide deck can?
Build it. The @AHAScience @KidneyInCVD Council is recognizing up to 3 educational tools.
Teams of students, residents, fellows & faculty may apply by Aug 7, 2026. @MLGumz
So proud of you!
Teaching AKI.
February 2019 as a med student vs. July 2026 as a Chief Resident.
There has been a lot of growth, failure, and learning in between.
Still have tons to learn!! :)
And of course, I had to teach it using my favorite @Neph_SIM AKI algorithm!
#NephTwitter
Laboratory of Vivek Bhalla, MD- Stanford retweeted
Congratulations @Tobias_B_Huber and Team this is really great news for the kidney community and our patients 🙌🙌🚀🚀❤️
HCKH-Launch-News: We officially launched the Hamburg Center for Kidney Health (HCKH) together with the leadership of the University of Hamburg (@unihh) and University Medical Center Hamburg-Eppendorf (@UKEHamburg), and distinguished international leaders from the European Renal Association (ERA) (@ERAkidney, @torra_roser), International Society of Nephrology (ISN) (@ISNkidneycare, @kidneydoc101), International Society of Glomerular Disease (ISGD) (@ISGDtweets), African Association of Nephrology (AFRAN) (@Rasha_Darwish_), NephCure Kidney International (@nephcure), Greifswald University (@uni_greifswald, @EndlichNicole) and UTMB (@utmbhealth, @JochenReiser) alongside patients, clinicians, scientists, and the next generation of kidney researchers.
HCKH is now among the world's leading academic platforms for kidney health, bringing together more than 250 kidney experts and internationally recognized programs spanning precision medicine, AI, systems biology, biobanking, integrated patient care, education, and translation.
Our ambition: to redefine kidney medicine, from understanding disease mechanisms to delivering precision therapies, and to translate scientific discovery into longer, healthier lives for people living with kidney disease.
A heartfelt thank you to our outstanding speakers, colleagues, patients, collaborators, partners in joint programs (@UniklinikAachen, @rkramann, @AarhusUni, @UKKoeln, @UK_Muenster, @Uniklinik_Fr, @SFB1453_NephGen, etc.), supporters, and the entire HCKH team for making this inaugural symposium such an inspiring milestone. This is only the beginning.
#HCKH #KidneyHealth #TeamScience #GlobalHealth #Innovation
Laboratory of Vivek Bhalla, MD- Stanford retweeted
Many congrats @KatherineTuttl8 !! The @KidneyInCVD council is so honored to have your lifetime achievements and contributions to the CKM space recognized ! @BhallaResearch @AHAScience @ASNKidney #SavingKidneysHeartsandLives @BaimInstitute
This quoted post is unavailable.
Laboratory of Vivek Bhalla, MD- Stanford retweeted
Watching Alexander Zverev compete at Roland-Garros, it is easy to see the athlete.
Diagnosed with Type 1 diabetes as a child, he is competing at the highest level of professional sport. His journey reflects decades of discoveries in insulin therapy, glucose monitoring, and diabetes care.
A reminder that biomedical research does not just change numbers in a paper. It changes lives.
For millions living with Type 1 diabetes, especially children, that matters. A quiet reminder that the disease may be part of your life, but it does not have to limit your dreams.
Laboratory of Vivek Bhalla, MD- Stanford retweeted
Hypertension (high blood pressure) is one of the most common complications of PKD. When hypertension is left untreated, it can further damage the kidneys and increase the risk of heart disease and stroke.
Learn more about managing this symptom of PKD: pkdcure.org/about-the-diseas…
Amazing. Remembering Michelle Winn’s work that pointed the way to this moment. pubmed.ncbi.nlm.nih.gov/1587…
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198 - The Lancet thelancet.com/journals/lance… @TheLancet
Laboratory of Vivek Bhalla, MD- Stanford retweeted
This month marks 10 years of JCI Insight!
A special shoutout to authors, editors, reviewers, readers, and all those dedicated to biomedical research, ranging from preclinical to clinical studies. This video highlights selected covers through the years.
—
Music: Bensound; License code: LDOZSSOUYFKAOLR8; Artist: Theatre Of Delays
@Eickelberg_MD
Please help us bring hope and light into this Holiday Season.
One of our @StanfordNeph @StanfordAbdTxp faculty families is working to save their child’s life from a rare genetic condition.
Please read, share and support.
rarebreak.org
Laboratory of Vivek Bhalla, MD- Stanford retweeted
Please help us bring hope and light into this Holiday Season.
One of our @StanfordNeph @StanfordAbdTxp faculty families is working to save their child’s life from a rare genetic condition.
Please read, share and support.
rarebreak.org
Laboratory of Vivek Bhalla, MD- Stanford retweeted
Congrats @StanfordMed scientists for publishing @ScienceTM showing how mRNA-based COVID vaccines can cause myocarditis via CXCL10-TNFy signaling axis.
@StanfordCVI @Stanford_ChEMH @StanfordDeptMed @stanfordimmuno @CellStanford @GreenstoneBio @brucegoldman med.stanford.edu/news/all-ne…
Laboratory of Vivek Bhalla, MD- Stanford retweeted
Thanks to Jordy and Tammy for their leadership on this important statement! @jordy_bc @TammyBradyMD
Cuffless devices estimate blood pressure (BP) indirectly. Most rely on sensors such as photoplethysmography (PPG) or tonometry, often combined with pulse transit/arrival time and machine learning. Outputs often represent BP change relative to calibration, not direct measurement.
Accuracy is particularly unclear in real-world use. Device performance is highly susceptible to motion, sensor positioning, body posture, and hydrostatic pressure effects. Yet most validation occurs immediately after calibration in static, controlled settings—leaving true real-world utility unproven.
✍🏼 @Jordy_bc @Tammybradymd @Rushellebyfield @Shakia_hardy @Spjuraschek @Deanp_bp @Roberththielemd @DrEugeneYang
Dissecting through renal physiology in the context of patient care is difficult but eminently valuable. Inspired by the landmark work of Hoorn et al., nature.com/articles/nm.2497 showing the effect of tacrolimus on phosphorylated NCC, we sought to understand if the use of CNIs 1/x.
Gitelman syndrome (GS) is a rare, autosomal-recessive salt-losing tubulopathy often requiring lifelong electrolyte supplementation. A new case report describes a patient with GS who initiated tacrolimus, a calcineurin phosphatase inhibitor, after orthotopic heart transplantation. The patient achieved normokalemia and improved blood pressure without needing potassium supplements. Read the full text for free: f.mtr.cool/zdgheeondv @AHAScience #AHAJournals
but there are only historical controls and multiple confounding factors in patients who receive tacrolimus (diuretics, PJP prophylaxis, PPIs, RAASi, etc). I'm thankful to Ms. Halee Yue @UCLAHealth and Dr. Martina Cacciapuoti @MartiCacciaNeph 3/x
who sought to sift through these factors to demonstrate that this could indeed work. There is lots to still do, both in lab and in clinic, and there are risks/benefits to calculate, but for those families suffering with a rare disease, this may be possible @StanfordNeph 4/x.